The results of this retrospective study focusing on r/r and secondary AML demonstrate, similarly to the findings of other researchers [10,11,19], that FLAG-Ida is a potent therapy; the overall response rate in our cohort of patients was 70%. The gene discussed is IDUA; the disease is acute myeloid leukemia.